{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32","upperLimit":"71","value":"53.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Amount of time a patient lives after treatment with IAP","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pravastatin sodium PO QD on days 1-8, idarubicin IV over 10-15 minutes on days 4-6, and cytarabine IV continuously on days 4-7. Treatment repeats every 28-56 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\npravastatin sodium: Given PO\n\nidarubicin: Given IV\n\ncytarabine: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Pravastatin Sodium, Idarubicin, and Cytarabine)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year after treatment with IAP","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of patients surviving"}